MedPath

To study the effects of a Unani formulation in patients with Psoriasis

Phase 2
Conditions
Health Condition 1: L400- Psoriasis vulgaris
Registration Number
CTRI/2023/03/050383
Lead Sponsor
Central Council for Research in Unani Medicine New Delhi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Clinically diagnosed patients of psoriasis.

2. Patients of both genders.

3. Patients in the age group of 10-60 years.

4. Clinically stable patients.

Exclusion Criteria

1. Childrens below 10 years.

2. Patients above 60 years.

3. Pregnant and lactating females.

4. Patients suffering from other concomitant diseases like dermatophytes, eczema, seborrheic dermatitis, Pityriasis Rosea.

5. Patients suffering from diabetes and malignancy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. Koebner phenomenon. <br/ ><br>2. Ring of worn off. <br/ ><br>3. Candle grease sign. <br/ ><br>4. Oil drop sign. <br/ ><br>5. KOH examination of skin scrap <br/ ><br>6. Auzpitz sign. <br/ ><br>7. Interleukin 17 and Interleukin 23. <br/ ><br>8. Psoriasis Area Severity Index (PASI). <br/ ><br>9. Dermatology Life Quality Index (DLQI) <br/ ><br>10. Photos of lesion (Before and After)Timepoint: 90 Days
Secondary Outcome Measures
NameTimeMethod
1. Erythematous plaques. <br/ ><br>2. Silvery scaling lesions. <br/ ><br>3. Itching. <br/ ><br>4. Visual Analog Scale (VAS). <br/ ><br>Timepoint: 90 Days
© Copyright 2025. All Rights Reserved by MedPath